| Symbol | ATNM |
|---|---|
| Name | ACTINIUM PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 100 PARK AVENUE,23RD FLOOR, NEW YORK, New York, 10017, United States |
| Telephone | (917) 415-1750 |
| Fax | — |
| — | |
| Website | https://www.actiniumpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Actinium develops Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML), which Actinium plans to advance with a potential strategic partner in the U.S. following completion of FDA interactions. The company continues to advance its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. Additional info from NASDAQ: |
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting
Read moreActinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting
Read moreActinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting
Read moreNew Form 8-K/A - Actinium Pharmaceuticals, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0001213900-26-034807 <b>Size:</b> 194 KB <br />Item 5.07: Submission of Matters to a Vote of Security Holders
Read moreActinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
Read more(99% Neutral) Actinium Pharmaceuticals Inc. (ATNM) Announces New Board Appointment
Read moreActinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
Read moreActinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium
Read more(99% Neutral) ACTINIUM PHARMACEUTICALS, INC. (ATNM) Announces Director Election
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06768905 | IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL | Phase1 | Non Hodgkin Lymphoma | Recruiting | 2025-04-25 | 2030-05-01 | ClinicalTrials.gov |
| NCT02575963 | Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients | Phase1 | AML | Completed | 2012-10-01 | 2020-05-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Allogeneic Hematopoietic Stem Cell Transplant (HSCT) | BIOLOGICAL | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| Total Body Irradiation (TBI) | RADIATION | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| Cyclophosphamide | DRUG | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| Fludarabine | DRUG | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| 131I-apamistamab | DRUG | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| Planar gamma imaging | RADIATION | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Exchange Transfusion | PROCEDURE | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Total Body Irradiation | DRUG | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Campath | DRUG | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Sirolimus | DRUG | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| 131I-apamistmab | DRUG | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| CAR-T cell | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Azacitidine | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT03932318 |
| Venetoclax | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT03932318 |
| Lintuzumab AC 225 | DRUG | Phase PHASE1 | Refractory Multiple Myeloma | TERMINATED | NCT02998047 |
| HCT | PROCEDURE | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02665065 |
| Conventional Care | DRUG | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02665065 |
| Iomab-B | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Spironolactone | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | UNKNOWN | NCT03867682 |
| Furosemide (Phase 1 only) | DRUG | Phase PHASE1 | AML | COMPLETED | NCT02575963 |
| Lintuzumab-Ac225 | BIOLOGICAL | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT03932318 |
| Cytarabine (Phase 1 only) | DRUG | Phase PHASE1 | AML | COMPLETED | NCT02575963 |
| ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195 | BIOLOGICAL | Phase PHASE1 | Leukemia | COMPLETED | NCT00672165 |